1stOncology™: Cancer Intelligence Service – Page 6046 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Kintara Therapeutics Announces Data Presentation at the 2022 American Association for Cancer Research Annual Meeting

On March 15, 2022 Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reported that it will be presenting data at the 2022 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (Press release, Kintara Therapeutics, MAR 15, 2022, View Source [SID1234610073]). The AACR (Free AACR Whitepaper) 2022 Annual Meeting will be held from April 8 through April 13, 2022 in New Orleans.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Data Presentation:

Track 24: Experimental and Molecular Therapeutics

Session PO.ET02.01 – Mechanisms of Drug Action 1

1843 / 15 – Dianhydrogalactitol (VAL-083) for the Treatment of Glioblastoma Multiforme (GBM): Impact of Glucose Transporters for Crossing the Blood Brain Barrier (BBB)

(Presentation Time: Monday, April 11, 2022 – 1:30 to 5:00 pm CT)

Immedica welcomes Heidi Ramstad as new Chief Medical Officer

On March 15, 2022 Immedica Pharma reported that Heidi Ramstad has been offered and accepted the position as Chief Medical Officer (CMO) at Immedica Pharma (Press release, Immedica Pharma, MAR 15, 2022, View Source [SID1234610072]).

Heidi is a Medical Doctor (MD) and Specialist in Pediatric Medicine. She has many years of academic and pharmaceutica industry experience. As an example, she has Medical Affairs experience from both big and small pharma, eg. being country and Nordic medical director for companies such as Pfizer, GSK and Roche. Recently she has held the position as CMO at the Swedish Biopharma company Oasmia.

We are very glad to bring Heidi onboard, and she will be an important contributor for the many activities and projects currently underway at Immedica.

Heidi will start her new role at Immedica at in April 2022 and she will report to Immedica CEO Anders Edvell. She will also be a member of the Immedica Executive Leadership Team.

ASLAN PHARMACEUTICALS APPOINTS DERMATOLOGY VETERAN DR ALEX KAOUKHOV AS CHIEF MEDICAL OFFICER

On March 15, 2022 ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, reported the appointment of Alex Kaoukhov, MD, as Chief Medical Officer based in ASLAN’s US office, effective immediately (Press release, ASLAN Pharmaceuticals, MAR 15, 2022, View Source [SID1234610069]).

Alex was most recently Head of Clinical Development, Senior Vice President at Bioniz Therapeutics where he established and managed a team responsible for the development of therapeutic assets for the treatment of skin and gastrointestinal autoimmune diseases.

Prior to this, from 2018 to 2020, Alex served as Head of Global Development at Almirall. His responsibilities included global clinical and non-clinical development, in addition to contributing to business development activities relating to building out the company’s medical dermatology pipeline, including the in-licensing of lebrikizumab for Europe.

Alex was also Associate Vice President of Clinical Development at Allergan in the US, with oversight of the medical dermatology pipeline. Before this, he served in clinical development leadership roles at Novartis and Galderma. During his career, Alex has designed and led large clinical trials, secured several product approvals for global programs and led the development of numerous innovative early-stage programs. At ASLAN, Alex replaces Dr Kenneth Kobayashi, who has left the company.

Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said: "We’re pleased to welcome Alex to the executive team. Alex brings a great breadth of international dermatology and immunology experience, with a particular focus in atopic dermatitis, and track record of strong project leadership and team building, especially related to developing and running late-stage clinical studies. As eblasakimab advances through the Phase 2b study and we firm up our development plans for ASLAN003, we are looking forward to benefitting from his insights and expertise. We are grateful to Ken for his contribution to the early eblasakimab program and wish him well."

Dr Alex Kaoukhov, Chief Medical Officer, ASLAN Pharmaceuticals, commented: "ASLAN is building an impressive pipeline of clinical assets that have the potential to offer truly differentiated options for patients. I am looking forward to working closely with the management team to lead the development of these programs at this critical stage and am very excited to join as eblasakimab is advancing through late-stage studies in atopic dermatitis."

Prior to joining industry, Alex trained in dermatology at the Université de Paris 7 – Denis Diderot and conducted clinical research at Hôpital Saint-Louis in Paris, France.

Pacylex Pharmaceuticals Announces Publication in Current Oncology of First Clinical Experience with an N-myristoyltransferase (NMT) inhibitor in a Patient with Diffuse Large B-cell Lymphoma (DLBCL)

On march 14, 2022 Pacylex Pharmaceuticals, an oncology company developing a first-in-class, oral drug for a new approach to cancer therapy, reported the publication in the journal Current Oncology of data from the first patient (Press release, Pacylex Pharmaceuticals, MAR 14, 2022, View Source [SID1234645061]). The paper entitled "Novel, First-in-Human, Oral PCLX-001 Treatment in a Patient with Relapsed Diffuse Large B-cell Lymphoma" describes how an eighty-six year old woman with relapsed diffuse large B-cell lymphoma (DLBCL) received oral PCLX-001, a small molecule, N-myristoyltransferase (NMT) inhibitor, as the initial patient in a phase 1 dose escalation clinical trial.

In this patient, daily oral administration of 20mg PCLX-001 tablets produced a pharmacokinetic profile suitable for single daily dosing: rapid oral absorption followed by an apparent elimination half-life of 16 hours, without systemic accumulation of drug by day 15. This Phase 1 study is primarily intended to determine the safety of PCLX-001 at escalating doses. There were no dose limiting toxicities and the patient completed their 28-day cycle without incident. Subsequently two additional patients successfully completed the 20 mg dose level without dose limiting toxicities and patients are now being dosed at 40 mg daily.

"We are encouraged that the first patient experience with an NMT inhibitor shows the initial dose to be well tolerated and rapidly absorbed, with a PK consistent with a daily oral drug" said John Mackey, CMO of Pacylex.

All three initial patients were enrolled at the Cross Cancer Institute. Dr. Randeep Sangha, the principal investigator for the study of PCLX-001 at the Cross Cancer Institute in Edmonton, said "our first dose level of PCLX-001 in two relapsed diffuse large B-cell lymphoma patients and a metastatic leiomyosarcoma patient went very smoothly and the safety results encouraged us to escalate to the next dose level and continue to explore its potential as a new treatment for patients".

Patient enrollment is continuing, and patients have also been dosed at Princess Margaret Hospital in Toronto and are expected to be dosed at Centre Hospitalier de l’Université de Montréal (CHUM) and the BC Cancer Agency in Vancouver. The study will enroll 20-30 patients in the initial phase. Four principal investigators will oversee the clinical study at the four clinical sites in Canada: Dr. John Kuruvilla at Princess Margaret Cancer Centre in Toronto, Dr. Randeep Sangha at the Cross Cancer Institute in Edmonton, Dr. Laurie Sehn at the British Columbia Cancer Center in Vancouver, and Dr. Rahima Jamal at CHUM in Montreal.

This study is registered at ClinicalTrials.gov Identifier: NCT04836195.

Iaso Therapeutics Receives Grant from the National Science Foundation for Next-Generation Vaccine Research

On March 14, 2022 Iaso Therapeutics, a research program focused on the development of novel technologies for next-generation vaccines, reported it has received a $978,597 grant from the National Science Foundation (NSF) for phase 2 of its development program (Press release, Iaso Therapeutics, MAR 14, 2022, View Source [SID1234626569]). The grant, titled Proprietary Bacteriophage Qβ Mutant as a Platform Carrier for Next-Generation Vaccines, will allow Iaso Therapeutics to acquire data and test its technology and methods to create powerful and versatile vaccine carriers for pre-clinical and clinical studies.

"Vaccines have become one of the most successful tools to protect us from deadly infectious diseases, and the COVID-19 pandemic only further highlighted this fact," said Robert Forgey, president and CEO at Iaso Therapeutics. "The funding we are receiving from the National Science Foundation will not only pave the way for the future of our program, but also serve as a large step forward in the treatment and management of diseases that were previously considered uncurable or untreatable."

Iaso Therapeutics’ bacteriophage Qβ mutants (mQβ) carrier technology was designed to elicit superior antibody responses for vaccines. By creating this carrier, Iaso Therapeutics aims to address a wide range of biomedical needs, including human infectious diseases like pneumonia and recurrent cancers.

"The National Science Foundation is proud to support the technology of the future by thinking beyond incremental developments and funding the most creative, impactful ideas across all markets and areas of science and engineering," said Andrea Belz, division director of the Division of Industrial Innovation and Partnerships at NSF. "With the support of our research funds, any deep technology startup or small business can guide basic science into meaningful solutions that address tremendous needs."

Prior to the grant from the NSF, Iaso Therapeutics successfully raised $2.25 million for phase 1 research through federal research grants, an investment from Red Cedar Ventures and the Michigan Economic Development Corporation’s Emerging Technology Fund.

"We are able to develop our technology thanks to the grants, investments and funding so vital to this research," said Dr. Xuefei Huang, founder and chief science officer at Iaso Therapeutics. "The carrier technology that we are creating, and testing will allow biotechnological companies to develop effective vaccines like never before. We see our mQβ technology addressing a wide range of biomedical needs to advance the health and welfare of the public."

To learn more about the science behind Iaso Therapeutics and stay up to date throughout phase 2, visit View Source